Acorda Therapeutics, Inc.
ACOR
Classifica tra le azioni
#39160
Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering,... Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing treatments for conditions affecting the nervous system, primarily within the United States. Its current product offerings include Ampyra (dalfampridine), an oral medication prescribed to enhance walking ability in individuals with multiple sclerosis (MS). The company also distributes Inbrija in Europe, which is used to manage "OFF" periods experienced by Parkinson's disease patients. Globally, Ampyra is recognized and sold as Fampyra across Europe, Asia, and the Americas. Beyond its existing products, Acorda is actively advancing several experimental therapies: ARCUS for the management of acute migraine attacks, rHIgM22 which has successfully completed Phase I clinical trials for MS, and Cimaglermin alfa, currently being investigated for patients with heart failure. The company holds a licensing and collaborative agreement with Biogen Inc. for the ongoing development and market distribution of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and operates from its headquarters in Ardsley, New York.
Prezzo delle azioni
$0.879
Ultima sincronizzazione: 2024-05-07
Capitalizzazione di mercato
$582.38K
Variazione (1 giorno)
9.88%
Variazione (1 anno)
8,690.00%
Paese
US
Scambia Acorda Therapeutics, Inc. (ACOR)
Categoria
Healthcare
Utile per Acorda Therapeutics, Inc. (ACOR)
Utile nel Mar 2024 TTM: $-304.44M
Secondo gli ultimi rapporti finanziari di Acorda Therapeutics, Inc., gli utili attuali della società sono $-304.44M. Nel 2022, la società ha registrato un utile di $-35.25M, un aumento rispetto a agli utili del 2021, che erano di $-109.07M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Acorda Therapeutics, Inc. dal 2016 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $-304.44M | 2.84% |
| 2023 | $-296.02M | 739.85% |
| 2022 | $-35.25M | -67.69% |
| 2021 | $-109.07M | 1.31% |
| 2020 | $-107.67M | -60.74% |
| 2019 | $-274.25M | -1,442.84% |
| 2018 | $20.42M | -108.11% |
| 2017 | $-251.89M | 495.92% |
| 2016 | $-42.27M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | -679.61% |
IN
|
